The possibilities of phytotherapy in the treatment of patients with functional disorders of the digestive tract
- Authors: Bakulin I.G1, Skazyvaeva E.V1, Avalueva E.B1, Skalinskaya M.I1, Oganezova I.A1
-
Affiliations:
- I.I.Mechnikov North-West State Medical University of the Ministry of Health of the Russian Federation
- Issue: Vol 19, No 8 (2017)
- Pages: 54-61
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/94868
- ID: 94868
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
I. G Bakulin
I.I.Mechnikov North-West State Medical University of the Ministry of Health of the Russian Federation
Email: igbakulin@yandex.ru
д-р мед. наук, проф., зав. каф. пропедевтики внутренних болезней, гастроэнтерологии и диетологии ФГБОУ ВО «СЗГМУ им. И.И.Мечникова» 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41
E. V Skazyvaeva
I.I.Mechnikov North-West State Medical University of the Ministry of Health of the Russian Federation
Email: skazyvaeva@yandex.ru
канд. мед. наук, доц. каф. пропедевтики внутренних болезней, гастроэнтерологии и диетологии ФГБОУ ВО «СЗГМУ им. И.И.Мечникова» 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41
E. B Avalueva
I.I.Mechnikov North-West State Medical University of the Ministry of Health of the Russian Federation
Email: avalueva@mail.ru
д-р мед. наук, проф. каф. пропедевтики внутренних болезней, гастроэнтерологии и диетологии ФГБОУ ВО «СЗГМУ им. И.И.Мечникова» 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41
M. I Skalinskaya
I.I.Mechnikov North-West State Medical University of the Ministry of Health of the Russian Federation
Email: mskalinskaya@yahoo.com
канд. мед. наук, доц. каф. пропедевтики внутренних болезней, гастроэнтерологии и диетологии ФГБОУ ВО «СЗГМУ им. И.И.Мечникова» 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41
I. A Oganezova
I.I.Mechnikov North-West State Medical University of the Ministry of Health of the Russian Federation
Email: oganezova@rambler.ru
д-р мед. наук, проф. каф. пропедевтики внутренних болезней, гастроэнтерологии и диетологии ФГБОУ ВО «СЗГМУ им. И.И.Мечникова» 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41
References
- Drossman D.A, Hasler W.L. Rome IV - Functional GI disorders: disorders of gut - brain interaction. Gastroenterology 2016; 150 (6): 1257-61.
- Маев И.В., Черемушкин С.В., Кучерявый Ю.А., Черемушкина Н.В. Синдром раздраженного кишечника. Римские критерии IV // Consilium Medicum. 2016; 18 (8): 79-85.
- Drossman D.A. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology 2016; 150: 1262-79.
- Jones M.P, Dilley J.B, Drossman D et al. Brain - gut connections in functional GI disorders: anatomic and physiologic relationships. Neurogastroenterol Motil 2006; 18: 91-103.
- Шептулин А.А., Курбатова А.А. Новые Римские критерии функциональной диспепсии IV пересмотра. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2016; 26 (4): 124-8.
- Mitchell C.M, Drossman D.A. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987; 92: 1282-4.
- Ottillinger B et al. STW 5 (Iberogast®) - a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr 2013; 163: 65-72.
- Agreus L, Svardsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: Overlap and lack of stability over time. Gastroenterology 1995; 109: 671-80.
- Keohane J. Functional Dyspepsia and Nonerosive Reflux Disease: Clinical Interactions and Their Implications. Med Gen Med 2007; 9 (3): 31.
- Oustamanolakis P, Tack J. Dyspepsia: organic versus functional. J Clin Gastroenterol 2012; 46 (3): 175-90.
- Young Wook Noh M.D, Hye-Kyung Jung M.D, Seong-Eun Kim M.D, Sung-Ae Jung M.D. Overlap of Erosive and Non - erosive Reflux Diseases With Functional Gastrointestinal Disorders According to Rome III Criteria. J Neurogastroenterol Motil 2010; 16 (2). doi: 10.5056/jnm.2010.16.2.148
- Калинин А.В., Логинов А.В., Хазанов А.И. Гастроэнтерология и гепатология: диагностика и лечение. Руководство для врачей. М.: МЕДпресс - информ, 2013 г.
- Авалуева Е.Б., Ткаченко Е.И., Сказываева Е.В. и др. Использование препаратов висмута в лечении синдрома раздраженного кишечника. Гастроэнтерология Санкт - Петербурга. 2013; 3-4: 11-4.
- Белоусова Л.Н., Пахомова И.Г. Синдром раздраженного кишечника. Новые возможности фармакопротекции РМЖ. Мед. обозрение. Клинические рекомендации и алгоритмы для практикующих врачей. Гастроэнтерология. 2014; 31: 2222-6.
- Itokawa H, Morris-Natschke S.L, Akiyama T, Lee K.H. Plant - derived natural product research aimed at new drug discovery. Nat Med 2008; 62: 263-80.
- Njuguna N.M, Masimirembwa C, Chibale K. Identification and characterization of reactive metabolites in natural products - driven drug discovery. Nat Prod 2012; 75: 507-13.
- Vinson B. Development of Iberogast®: clinical evidence for multicomponent herbal mixtures. In: Cooper R, Kronenberg F, editors. Botanical medicine: from bench to bedside. New Rochelle: Mary Ann Liebert, 2009; p. 167-89.
- Мазнев Н.И. Энциклопедия лекарственных средств. 3-е изд., испр. и доп. М., 2004.
- Heinle H, Hagelauer D, Pascht U et al. Intestinal spasmolytic effects of STW 5 (Iberogast®) and its components. Phytomedicine 2006; 13: SV 75-9.
- Ammon H.P, Kelber O, Okpanyi S.N. Spasmolytic and tonic effect of STW 5 (Iberogast) in intestinal smooth muscle. Phytomedicine 2006; 13: SV 67-74.
- Liu C.Y, Müller M.H, Glatzle J et al. The herbal preparation STW 5 (Iberogast®) desensitizes intestinal afferents in the rat small intestine. Neurogastroenterol Motil 2004; 16: 759-64.
- Simmen U, Kelber O, Okpanyi S.N et al. Bimding of STW 5 (Iberogast) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors. Phytomedicine 2006; 13: 51-5.
- Khayyal M.T, Seif-El-Nasr M, El-Ghazaly M.A et al. Mechanisms involved in the gastro - protective effect of STW 5 (Iberogast) and its components against ulcers and rebound activity. Phytomedicine 2006; 13: SV 56-66.
- Khayyal M.T, El-Ghazaly M.A, Kenawy S.А et al. Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination. Arzneimittel Forsch/Drug Res 2001; 51: 545-53.
- Schempp H, Totha A, Weiser D, Elstnera E. Antioxidative Properties of Iberis amara Extracts in Biochemical Model Reactions. Arzneim - Forsch/Drug Res 2003; 53 (8): 568-77.
- Germann I et al. Antioxidative properties of the gastrointestinal phytopharmaceutical remedy STW 5 (Iberogast®). Phytomedicine 2006; 13: 143-9.
- Michael S, Kelber O, Vinson B, Nieber K. Herbal preparations STW 5 and STW 6 inhibit inflammation - mediated motility disorders in the ileum. Gut 2006; 55: SV A206.
- Abdel-Aziz H, Wadie W, Kelber O et al. Anti inflammatory effect of STW5 in colonic inflammation in vivo. Gut 2007; 56: A154.
- Schempp H, Weiser D, Kelber O, Elstner E.F. Radical scavenging and anti infl ammatory properties of STW 5 and its components. Phytomedicine 2006; 13: SV 36-44.
- Kruger D, Zeller F, Kellber O et al. The phytopharmacon STW 5 (Iberogast) has pro - secretory effects of the human small and large intestine. Gut 2007; 55 (Suppl. V): A94.
- Ritter R et al. Clinical trial on standardised celandine extract in patients with functional epigastric complaints: results of a placebo - controlled double - blind trial. Complement Ther Med 1993; 1: 189-93.
- Harries N et al. Antifoaming and carminativeaction of volatile oils. J Clin Pharmacy 1978; 2: 171-7.
- Krüger D, Gruber L, Angay O et al. Efficacy profile of STW 5 (Iberogast) offers new options for treatment of gastrointestinal diseases. Z Phytother 2008; 29: S29.
- Schemann M, Michel K, Hohenester B, Rühl A. Region specific effects of STW 5 and its components in gastric fundus, corpus and antrum. Phytomedicine 2006; 13: SV 90-9.
- Pilichiewicz A.N, Horowitz M, Russo A et al. Effects of Iberogast on proximal gastric volume, antropyloroduodenal (APD) motility and gastric emptying in healthy men. Am J Gastroenterol 2007; 102: 1-8.
- Vinson B.R, Holtmann G. Onset of action and efficiency of STW 5 in the clinical setting in patients with functional dyspepsia and irritable bowel syndrome. Gastroenterology 2013; 144 (5, Supp. 1): 682 (Mo1881).
- Ottillinger B et al. STW 5 (Iberogast®) - a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr 2013; 163: 65-72.